7Baggers
Quarterly
Annual
    Unit: USD2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 
      
    		       
      operating activities:
    		       
      net income
    		-5,739,000 -8,654,000 -5,794,000 -7,000 468,000 -2,734,000 -2,342,000 
      adjustments to reconcile net income to cash from operating activities:
    		       
      depreciation
    		32,000 33,000 35,000 35,000 35,000 32,000  
      stock-based compensation
    		563,000 621,000 821,000 1,005,000 952,000 972,000 1,046,000 
      net unrealized (gain) loss on foreign currency transactions
    		-370,000 -49,000      
      amortization of investments
    		0 -14,000  -166,000 -241,000 -278,000  
      deferred revenue
    		  -2,067,000 -6,363,000 -4,930,000 -2,368,000 -2,523,000 
      changes in operating assets and liabilities:
    		       
      accounts receivable
    		  5,009,000 885,000 -846,000 -1,313,000 34,000 
      prepaid expenses and other current assets
    		1,273,000 303,000 277,000 -10,000 2,528,000 -520,000 -750,000 
      accounts payable
    		1,745,000 381,000 -949,000 -843,000 1,756,000 -1,959,000 1,046,000 
      accrued expenses
    		-515,000 -786,000 -1,534,000 -1,858,000 1,239,000 -1,011,000 -1,710,000 
      right-of-use assets and lease liabilities
    		-2,000 -4,000 -5,000 7,000 -7,000 -4,000 24,000 
      net cash from operating activities
    		-3,013,000 -8,169,000 -3,299,000 -7,657,000 730,000 -8,800,000 -5,664,000 
      capex
    		0 -4,000 -4,000 0 -62,000 40,000 -35,000 
      free cash flows
    		-3,013,000 -8,173,000 -3,303,000 -7,657,000 668,000 -8,760,000 -5,699,000 
      investing activities:
    		       
      purchases of property and equipment
    		0 -4,000 -4,000 0 -62,000 -19,000 -35,000 
      purchases of short-term investments
    		  0 0 -10,289,000 -7,312,000 -17,531,000 
      maturities of short-term investments
    		0 4,500,000 6,000,000 12,000,000 9,000,000 4,500,000 12,000,000 
      net cash from investing activities
    		0 4,496,000 5,996,000 12,000,000 -1,351,000 -2,831,000 -5,566,000 
      financing activities:
    		       
      proceeds from exercise of stock options
    		0 38,000      
      proceeds from issuance of common stock under atm facility, net of issuance costs
    		-16,000 53,000      
      net cash from financing activities
    		-16,000 91,000 73,000 0   79,000 
      effect of exchange rate changes on cash and cash equivalents
    		22,000 -1,000 -133,000 48,000 19,000 -17,000 -15,000 
      net decrease in cash and cash equivalents
    		-3,007,000 -3,583,000 2,637,000 4,391,000 -511,000 -11,648,000  
      cash and cash equivalents at beginning of period
    		0 18,085,000 0 0 0 23,216,000 0 
      cash and cash equivalents at end of period
    		-3,007,000 14,502,000 2,637,000 4,391,000 -511,000 11,568,000 -11,166,000 
      supplemental cash flow information:
    		       
      atm facility issuance costs reclassed from other current assets
    		0 392,000      
      atm facility issuance costs in accrued expenses
    		-16,000 99,000      
      amounts included in accounts payable for purchases of property and equipment
    		     59,000  
      net unrealized loss on foreign currency transactions
    		    -224,000 383,000 -357,000 
      amortization of term loan discount and issuance costs
    		      0 
      amortization of premium on investments
    		       
      repayment of notes payable
    		      0 
      common stock repurchased
    		      0 
      proceeds from issuance of common stock under employee stock purchase plan
    		  69,000 0   79,000 
      cash paid for interest
    		       
      cash paid for income taxes
    		       
      principal repayments on notes payable
    		       
      acquired in-process research and development
    		       
      amortization of premium and accretion of discounts on investments
    		      -165,000 
      cash acquired in bioniz acquisition
    		       
      net increase in cash and cash equivalents
    		       
      fair value of bioniz assets acquired
    		       
      issuance of common stock for bioniz acquisition
    		       
      bioniz net liabilities assumed
    		       
      depreciation and amortization
    		       
      property and equipment in accounts payable
    		       
      proceeds from issuance of common stock from follow-on offering, net of issuance costs
    		       
      proceeds from espp purchases
    		       
      right-of-use assets obtained in exchange for lease obligations
    		       
      net unrealized gain on foreign currency transactions
    		       
      non-cash consulting expense
    		       
      realized gain on investments
    		       
      right-of-use assets, operating leases
    		       
      operating lease liabilities
    		       
      proceeds from registered direct offering, net of offering costs
    		       
      proceeds from issuance of common stock under atm, net of issuance costs
    		       
      issuance of commitment shares to lincoln park pursuant to agreement
    		       
      amortization/accretion of investments
    		       
      proceeds from issuance of common stock under atm facilities, net of issuance costs
    		       
      proceeds from issuance of notes payable, net of issuance costs
    		       
      fair value of common stock warrants in connection with issuance of notes payable
    		       
      atm issuance costs in accrued expenses
    		       
      deferred rent
    		       
      non-cash interest expense
    		       
      change in fair value of biocon anti-dilution right
    		       
      accretion of discount on investments
    		       
      other non-cash income and expenses
    		       
      proceeds from public offering of common stock, net of 2,123 issuance costs
    		       
      proceeds from issuance of convertible promissory notes
    		       
      proceeds from exercise of stock options, including early exercise
    		       
      proceeds from espp purchase
    		       
      conversion of convertible promissory notes into common stock
    		       
      issuance of common stock to biocon pursuant to certain anti-dilution rights
    		       
      non-cash research license expense
    		       
      proceeds from public offering of common stock, net of 2,123,106 issuance costs
    		       
      proceeds from issuance of convertible promissory notes related party
    		       
      proceeds from issuance of common stock
    		       
      supplemental disclosures of noncash activities:
    		       
      issuance of common stock to biocon for license
    		       
    The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.